Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-12

Clinical Trial Update: Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating the efficacy and safety of a one-month degarelix dosing regimen in Korean patients with prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-02-12